- Home
- CKPT vs FTLF Comparison
CKPT vs FTLF Comparison
Compare CKPT & FTLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- FTLF
- Stock Information
- Founded
- CKPT 2014
- FTLF 2005
- Country
- CKPT United States
- FTLF United States
- Employees
- CKPT N/A
- FTLF N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- FTLF Medicinal Chemicals and Botanical Products
- Sector
- CKPT Health Care
- FTLF Health Care
- Exchange
- CKPT Nasdaq
- FTLF Nasdaq
- Market Cap
- CKPT 172.4M
- FTLF 145.8M
- IPO Year
- CKPT 2017
- FTLF N/A
- Fundamental
- Price
- CKPT $3.13
- FTLF $15.44
- Analyst Decision
- CKPT Strong Buy
- FTLF Strong Buy
- Analyst Count
- CKPT 3
- FTLF 1
- Target Price
- CKPT $12.00
- FTLF $20.00
- AVG Volume (30 Days)
- CKPT 753.4K
- FTLF 15.2K
- Earning Date
- CKPT 03-21-2025
- FTLF 03-04-2025
- Dividend Yield
- CKPT N/A
- FTLF N/A
- EPS Growth
- CKPT N/A
- FTLF 93.67
- EPS
- CKPT N/A
- FTLF 0.85
- Revenue
- CKPT $47,000.00
- FTLF $62,755,000.00
- Revenue This Year
- CKPT N/A
- FTLF $25.54
- Revenue Next Year
- CKPT $300,658.78
- FTLF $7.30
- P/E Ratio
- CKPT N/A
- FTLF $18.16
- Revenue Growth
- CKPT N/A
- FTLF 40.17
- 52 Week Low
- CKPT $1.38
- FTLF $10.51
- 52 Week High
- CKPT $4.50
- FTLF $17.75
- Technical
- Relative Strength Index (RSI)
- CKPT 46.36
- FTLF 49.41
- Support Level
- CKPT $3.10
- FTLF $14.75
- Resistance Level
- CKPT $3.43
- FTLF $15.49
- Average True Range (ATR)
- CKPT 0.26
- FTLF 0.63
- MACD
- CKPT 0.00
- FTLF 0.00
- Stochastic Oscillator
- CKPT 33.03
- FTLF 35.29
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About FTLF FitLife Brands Inc.
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, and sports drink products, meal replacement products and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products and Supplements.